

In a further aspect, the disclosure provides a protein comprising

- (i) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79,
- 5 (ii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:74 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79, or
- (iii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79, or
- 10 (iv) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:80, or
- (v) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:74 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:80, or
- 15 (vi) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:80, or
- 20 (vii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:105, or

and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79, SEQ ID NO:80 or SEQ ID NO:105.

The disclosure also provides an isolated nucleic acid molecule i) encoding a first antigen binding unit and/or a second antigen binding unit of a protein of the disclosure, optionally  
5 further encoding a first and/or a second Fc domain, or ii) encoding a first and/or a second polypeptide chain of a protein of the disclosure. The disclosure also provides expression vectors comprising the nucleic acid molecule of the disclosure, host cells transfected with such expression vectors, and methods of manufacturing a protein of the disclosure. In a further aspect, provided herein is a host cell transfected with two expression vectors, one  
10 expression vector encoding a first polypeptide chain of any one of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75 and another expression vector encoding a second polypeptide chain of SEQ ID NO:79, SEQ ID NO:80 or SEQ ID NO:105. In a further aspect, provided herein is a method of manufacturing a protein of the disclosure comprising i) cultivating the host cell of disclosure under conditions allowing expression of the protein of the  
15 disclosure; and, ii) recovering the protein.

In a further aspect, provided herein is a protein comprising a first polypeptide chain specifically binding to DLL3 and a second polypeptide chain specifically binding to CD3, wherein said first polypeptide chain comprises a first light chain, a first peptide linker, and a first heavy chain and said second polypeptide chain comprises a second light chain, a  
20 second peptide linker, and a second heavy chain, wherein the C-terminus of said first light chain is covalently linked to the N-terminus of said first heavy chain via said first peptide linker and wherein the C-terminus of said second light chain is covalently linked to the N-terminus of said second heavy chain via said second peptide linker,

and wherein said first polypeptide chain specifically binding to DLL3 comprises a light  
25 chain variable domain and heavy chain variable domain comprising CDR sequences selected from the group consisting of i) to iii):

In a further aspect, the disclosure provides the protein of the disclosure for use in medicine.

In a further aspect, the disclosure provides a pharmaceutical composition comprising the protein of the disclosure and a pharmaceutically acceptable carrier.

5 In a further aspect, the disclosure provides a use of the protein of the disclosure in preparing a pharmaceutical composition for treating a DLL3 expressing cancer.

In a further aspect, the disclosure provides the protein of the disclosure for use in treating a DLL3 expressing cancer.

10 Further examples, uses and methods involving the binding proteins of the disclosure will become clear from the following detailed description of the disclosure and from the appended claims.

## CLAIMS

1. A protein comprising a first antigen binding unit specifically binding to DLL3 and a second antigen binding unit specifically binding to CD3, wherein said first antigen binding unit specifically binding to DLL3 is selected from the group consisting of i) to iii):
  - i) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3);
  - ii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3); and
  - iii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3).
2. The protein of claim 1, wherein said first antigen binding unit specifically binding to DLL3 comprises a first light chain variable domain and a first heavy chain variable domain and is selected from the group consisting of i) to iii):
  - i) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:38;
  - ii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequences of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:40; and

- iii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42.
3. The protein of claims 1 or 2, wherein said second antigen binding unit specifically binding to CD3 is selected from the group consisting of i)-iii):
- i) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3);
  - ii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); and
  - iii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:96 (CDR1), SEQ ID NO:97 (CDR2) and SEQ ID NO:98 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:99 (CDR1), SEQ ID NO:100 (CDR2) and SEQ ID NO:101 (CDR3).
4. The protein of any one of claims 1 to 3, wherein said second antigen binding unit specifically binding to CD3 comprises a second light chain variable domain and a second heavy chain variable domain selected from the group consisting of i) to iii):
- i) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68;
  - ii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; and

- iii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:102 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:103.

5. The protein of claim 1 or 3, wherein

- (i) said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3); or
- (ii) said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3); or
- (iii) said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs

comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3); or

- (iv) said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); or
- (v) said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); or
- (vi) said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3).

6. The protein of claim 5, wherein said first antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3), and said second antigen binding unit comprises light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3).

7. The protein of any one of claims 1 to 4, wherein

- (i) said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:38, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68; or
- (ii) said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:40, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68; or
- (iii) said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68; or
- (iv) said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37 and heavy chain

variable domain comprising the amino acid sequence of SEQ ID NO:38, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; or

(v) said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:40, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; or

(vi) said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70.

8. The protein of claim 7, wherein said first antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42, and said second antigen binding unit comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68.

9. The protein of any one of claims 1 to 8, wherein

i) said first antigen binding unit specifically binding to DLL3 comprises from its N- to C-terminus a first light chain variable domain, a first light chain constant domain, a first peptide linker, a first heavy chain variable domain and a first heavy chain constant CH1 domain; and

- ii) said second antigen binding unit specifically binding to CD3 comprises from its N- to C-terminus a second light chain variable domain, a second light chain constant domain, a second peptide linker, a second heavy chain variable domain and a second heavy chain constant CH1 domain.
10. The protein of claim 9, wherein said first and/or second peptide linker comprises 26 to 42 amino acids, 30 to 40 amino acids, 34 to 40 amino acids, or 36 to 39 amino acids.
11. The protein of claims 9 or 10, wherein said first peptide linker and/or second peptide linker is a Gly-Ser linker comprising the amino acid sequence of SEQ ID NO:89, and wherein said first and second peptide linker comprise the same sequence.
12. The protein of any one of claims 9 to 11, wherein
- (i) said first antigen binding unit comprises the amino acid sequence of SEQ ID NO:49, and said second antigen binding unit comprises the amino acid sequence of SEQ ID NO:71; or
  - (ii) said first antigen binding unit comprises the amino acid sequence of SEQ ID NO:50, and said second antigen binding unit comprises the amino acid sequence of SEQ ID NO:71; or
  - (iii) said first antigen binding unit comprises the amino acid sequence of SEQ ID NO:51, and said second antigen binding unit comprises the amino acid sequence of SEQ ID NO:71; or
  - (iv) said first antigen binding unit comprises the amino acid sequence of SEQ ID NO:49, and said second antigen binding unit comprises the amino acid sequence of SEQ ID NO:72; or
  - (v) said first antigen binding unit comprises the amino acid sequence of SEQ ID NO:50, and said second antigen binding unit comprises the amino acid sequence of SEQ ID NO:72; or
  - (vi) said first antigen binding unit comprises the amino acid sequence of SEQ ID NO:51, and said second antigen binding unit comprises the amino acid sequence of SEQ ID NO:72.

13. The protein of any one of claims 9 to 12 further comprising a first and a second Fc domain, said first Fc domain covalently linked to said first antigen binding unit, and a said second Fc domain covalently linked to said second antigen binding unit.

14. The protein of claim 13, wherein

- i) said first Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and said second Fc domain comprises a threonine (T) at position 407 [Y407T], or
- ii) said first Fc domain comprises a tryptophan (W) at position 366 [T366W], and said second Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], or
- iii) said second Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and said first Fc domain comprises a threonine (T) at position 407 [Y407T], or
- iv) said second Fc domain comprises a tryptophan (W) at position 366 [T366W], and said first Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V].

15. The protein of claim 14, wherein said first and/or said second Fc domain further comprises an alanine at position 234[L234A] and at position 235 [L235A].

16. The protein of any one of claims 9 to 15, wherein the first light chain constant domain and the second light chain constant domain comprise a human kappa or lambda domain.

17. A protein comprising

- (i) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79,
- (ii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:74 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79, or

- (iii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79, or
- (iv) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:80, or
- (v) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:74 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:80, or
- (vi) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:80, or
- (vii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:73 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:105, or
- (viii) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:74 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:105, or
- (ix) a first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:105.

18. The protein of claim 17, wherein said first polypeptide chain specifically binding to DLL3 comprising the amino acid sequence of SEQ ID NO:75 and said second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79.

19. A host cell transfected with two expression vectors, one expression vector encoding a first polypeptide chain of any one of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75 and another expression vector encoding a second polypeptide chain of SEQ ID NO:79, SEQ ID NO:80 or SEQ ID NO:105.

20. A method of manufacturing a protein of claim 17 comprising

- i) cultivating the host cell of claim 19 under conditions allowing expression of the protein of claim 17; and,
- ii) recovering the protein.

21. A protein comprising a first polypeptide chain specifically binding to DLL3 and a second polypeptide chain specifically binding to CD3, wherein said first polypeptide chain comprises a first light chain, a first peptide linker, and a first heavy chain and said second polypeptide chain comprises a second light chain, a second peptide linker, and a second heavy chain, wherein the C-terminus of said first light chain is covalently linked to the N-terminus of said first heavy chain via said first peptide linker and wherein the C-terminus of said second light chain is covalently linked to the N-terminus of said second heavy chain via said second peptide linker, and wherein said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising CDR sequences selected from the group consisting of i) to iii):

- i) light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and a heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3);
- ii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3); and
- iii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3).

22. The protein of claim 21, wherein said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and heavy chain variable domain comprising CDR sequences selected from the group consisting of i) to iii):

- i) light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3);
- ii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); and
- iii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:96 (CDR1), SEQ ID NO:97 (CDR2) and SEQ ID NO:98 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:99 (CDR1), SEQ ID NO:100 (CDR2) and SEQ ID NO:101 (CDR3).

23. The protein of claim 22, wherein

- i) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3); or
- ii) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8

(CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3); or

iii) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3); or

iv) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); or

- v) light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); or
- vi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3).

24. The protein of claim 23, wherein said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3); and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3).

25. The protein of any one of claims 21 or 22, wherein said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and a heavy chain variable domain selected from the group consisting of i) to iii):

- i) a light chain variable domain comprising the amino acid sequences of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:38;
- ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:40; and
- iii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42.

26. The protein of any one of claims 21, 22 or 25 wherein said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain selected from the group consisting of i)-iii):

- i) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68;
- ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; and
- iii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:102 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:103.

27. The protein of claims 25 or 26, wherein

- (i) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequences of SEQ ID

NO:38; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68; or

- (ii) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:40; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68; or
- (iii) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:42; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68; or
- (iv) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:38; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; or
- (v) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:40; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; or

(vi) said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:42; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70.

28. The protein of claim 27, wherein said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain comprising the amino acid sequences of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:42; and said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68.

29. The protein of any one of claims 21 to 28, wherein said first and/or second peptide linker comprises 26 to 42 amino acids, 30 to 40 amino acids, 34 to 40 amino acids, or 36 to 39 amino acids.

30. The protein of claim 29, wherein said first peptide linker and/or second peptide linker is a Gly-Ser linker comprising the amino acid sequence of SEQ ID NO:89, and wherein said first and second peptide linker comprise the same sequence.

31. The protein of any one of claims 21 to 30, wherein

- (i) said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:49, and said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:71; or
- (ii) said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:50, and said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:71; or

- (iii) said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:51, and said second polypeptide chain unit comprises the amino acid sequence of SEQ ID NO:71; or
  - (iv) said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:49, and said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:72; or
  - (v) said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:50, and said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:72; or
  - (vi) said first polypeptide chain unit comprises the amino acid sequence of SEQ ID NO:51, and said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:72.
32. The protein of claim 31, wherein said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:51, and said second polypeptide chain unit comprises the amino acid sequence of SEQ ID NO:71.
33. The protein of any one of claims 21 to 32, wherein
- i) said first heavy chain comprises a tyrosine (Y) at position 366 [T366Y], and said second heavy chain comprises a threonine (T) at position 407 [Y407T], or
  - ii) said first heavy chain comprises a tryptophan (W) at position 366 [T366W], and said second heavy chain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], or
  - iii) said second heavy chain comprises a tyrosine (Y) at position 366 [T366Y], and said first heavy chain comprises a threonine (T) at position 407 [Y407T], or
  - iv) said second heavy chain comprises a tryptophan (W) at position 366 [T366W], and said first heavy chain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V].
34. The protein of claim 33, wherein said first and/or said second heavy chain further comprises an alanine at position 234[L234A] and at position 235 [L235A].

35. The protein of any one of claims 21 to 34, wherein said first light chain and said second light chain comprise a human kappa or lambda domain.
36. The protein of any one of claims 1 to 18 or 21 to 35 for use in medicine.
37. A pharmaceutical composition comprising the protein of any one of claims 1 to 18 or 21 to 35 and a pharmaceutically acceptable carrier.
38. Use of the protein of any one of claims 1 to 18 or 21 to 35 in preparing a pharmaceutical composition for treating a DLL3 expressing cancer.
39. The protein of any one of claims 1 to 18 or 21 to 35 for use in treating a DLL3 expressing cancer.
40. The use of claim 38 or the protein for use of claim 39, wherein the cancer is SCLC, glioblastoma or a DLL3 expressing neuroendocrine tumor.
41. The use of claim 38 or 40, or the protein for use of claim 39 or 40, wherein said protein is used in combination with a chemotherapeutic agent, a therapeutically active compound that inhibits angiogenesis, a signal transduction pathway inhibitor, an EGFR inhibitor, an immune modulator, an immune checkpoint inhibitor, or a hormonal therapy agent.
42. The use or protein for use of claim 41, wherein said protein is in combination with an immune checkpoint inhibitor, preferably an anti- PD-1 antibody or an anti-PD-L1 antibody.
43. The use or protein for use of claim 42, wherein the anti-PD-1 antibody is selected from the group consisting of PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5.